In April 2012, the FDA released proposed regulations regarding the Federal Prescription Drug Sample Transparency provisions of Section 6004 of the Affordable Care Act.
This complimentary webinar investigates the FDA's requirements for sample transparency reporting on October 1, 2012.
John Oroho and Chrissy Bradshaw compare PDMA obligations and new sample requirements, and delve into the scope of the requirements, including whether or not the provisions extend to coupons and vouchers.
To watch the webinar, please click the video below:
Disclaimer: Please keep in mind that laws are constantly changing and the content of materials on this website may not reflect their current status.